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Abstract
 
Aim
 
The efficacy and safety of insulin aspart (IAsp), a rapid-acting human insulin analogue, were compared with regular
human insulin (HI) as the bolus component of basal-bolus therapy for subjects with gestational diabetes mellitus (GDM).
 
Methods
 
In a randomized, parallel-group, open-labelled trial, 27 women with GDM (age 30.7 
 
±
 
 6.3 years, HbA
 
1c
 
< 7%) were randomized to receive IAsp (5 min before meal) or HI (30 min before meal). The trial period extended from
diagnosis of GDM (18–28 weeks) to 6 weeks postpartum.
 
Results
 
Both treatment groups maintained good overall glycaemic control during the study (beginning and end of study
HbA
 
1c
 
 
 
≤
 
 6%). During the meal test, mean glucose at week 6 (IAsp 4.2 
 
±
 
 0.57 mmol/l, HI 4.8 
 
±
 
 0.86 mmol/l) was slightly
lower than at week 0 (IAsp 4.9 
 
±
 
 0.59 mmol/l, HI 5.1 
 
±
 
 0.36 mmol/l). However, change from baseline values for average
glucose (IAsp –1.09 
 
±
 
 0.54 mmol/l, HI –0.54 
 
±
 
 0.74 mmol/l; 
 
P
 
 = 0.003) and C-peptide (IAsp –0.50 
 
±
 
 0.67 nmol/l, HI
–0.30 
 
±
 
 0.70 nmol/l; 
 
P
 
 = 0.027) were significantly lower after IAsp treatment than HI treatment. No major hypoglycaemic
events were reported during the study. Cross-reacting insulin antibody binding increased slightly from baseline in both
treatments groups (end of study: IAsp 2.1 
 
±
 
 5.4%, HI 6.4 
 
±
 
 13.9%), whereas antibodies specific to IAsp or HI remained
relatively low (< 1% binding).
 
Conclusion
 
IAsp was more effective than HI in decreasing postprandial glucose concentrations. Duration of IAsp injection
5 min before a meal rather than 30 min prior to meals offers a more convenient therapy for subjects with GDM. Overall
safety and effectiveness of IAsp were comparable to HI in pregnant women with GDM.
Diabet. Med. 24, 1129–1135 (2007) 
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Introduction
 
Gestational diabetes mellitus (GDM) is defined as glucose
intolerance that occurs during pregnancy [1–3]. GDM affects
about 7% of all pregnancies, resulting in > 200 000 cases per
year [2]. Depending on the population sample and diagnostic
criteria, the prevalence may range from 1 to 14% [1,2]. Of all
the pregnancies complicated by diabetes, GDM accounts for
about 90% [1]. Pregnancy complicated by GDM increases the
risk of both maternal and neonatal complications. Women
with GDM are at high risk of developing overt Type 2 diabetes
months or years postpartum [4,5]. The most common and
significant neonatal complication associated with GDM is macro-
somia [6], which occurs at rates as high as 40% of neonates in
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untreated GDM [7]. In addition, neonatal macrosomia is
associated with the metabolic syndrome of hyperinsulinaemia
and deposition of fat in the visceral cavity [8]. Other neonatal
complications include hypoglycaemia, hyperbilirubinaemia,
hypocalcaemia, and erythraemia [9].
The diagnosis of GDM can be made based on the 75-g, 2-h
oral glucose tolerance test (OGTT) [10] or on 100-g, 3-h OGTT
criteria developed by the National Diabetes Data Group as
modified by Carpenter and Coustan [11]. Tight glycaemic
control both pre- and postprandially is of critical importance
and has been shown to have an impact on neonatal outcome
[12,13]. The standard treatment approach for GDM is an
intensified insulin regimen if diet therapy alone fails to
restore adequate glycaemic control [fasting blood glucose (BG)
< 5.0 mmol/l (90 mg/dl) and 1-h postprandial BG < 6.7 mmol/l
(120 mg/dl) determined from capillary blood] [14]. Adequate
insulin therapy should not only be effective in achieving
glycaemic control, but also utilize formulations that have a low
immunogenic potential [15]. As shown by Menon 
 
et al.
 
, insulin–
antibody complexes may cross the placenta and be associated
with the development of macrosomia in the infant [15]. Since
the high probability of development of Type 2 diabetes in
females with a history of GDM may be explained on the basis of
pregnancy-induced acceleration of pancreatic 
 
β
 
-cell secretory
exhaustion, treatment that would produce a 
 
β
 
-cell-sparing
effect on endogenous insulin secretion could prove beneficial.
Jovanovic 
 
et al
 
. have documented that women with GDM
who received a rapid-acting insulin analogue (insulin lispro) in
a 6-week study had significantly lower postprandial increases
in plasma C-peptide (and hence in endogenous insulin secretion)
than those who injected regular human insulin [16]. In addi-
tion, better overall glycaemic control (mean decrease from
baseline HbA
 
1c
 
: insulin lispro 0.35%, vs. regular insulin 0.07%;
 
P
 
 < 0.005) was achieved in insulin lispro-treated individuals
than in women receiving regular human insulin as a component
of a basal-bolus regimen. Based on these findings, a hypothesis
was proposed that use of a rapid-acting insulin analogue,
insulin aspart (IAsp), may improve postprandial glycaemia
during pregnancy complicated by gestational diabetes. This
hypothesis sets the conceptual framework for studying IAsp in
GDM. The short-term efficacy of IAsp has been demonstrated
in a study of 15 women with GDM during standardized meal
tests, where insulin aspart was shown to be effective in decreas-
ing postprandial glucose concentration [17]. The present study
further assesses whether IAsp is a safe and effective alternative
to regular human insulin for overall glycaemic control in subjects
with GDM. Thus, the primary end-points were adequate control
of plasma glucose and lack of significant immunogenicity.
 
Patients and methods
 
The study was performed with the approval of the Cottage
Health Systems institutional review board at the study site.
Written informed consent was obtained from all subjects before
any trial-related activities were initiated. In this single-centre,
randomized, parallel-group, open-label trial, 27 women (age
30.7 
 
±
 
 6.3 years, HbA
 
1c
 
 < 7.0% at diagnosis, able and willing
to perform self-measured BG readings seven times a day and
inject insulin at least four times a day) with GDM, were
randomized to receive either IAsp (NovoLog®; Novo Nordisk
A/S, Bagsvaerd, Denmark) 5 min before meal or regular human
insulin (HI, Novolin R; Novo Nordisk A/S) 30 min before meal.
Insulin was administered using the NovoPen® 3 injection
device. Subjects also received insulin NPH (Novolin N; Novo
Nordisk A/S) as the basal insulin. The trial period extended
from the diagnosis of insulin requiring GDM (18–28th week of
pregnancy) to 6 weeks postpartum.
The initial treatment regimen consisted of two daily doses
(morning and bedtime) of NPH and three daily doses of either
IAsp or HI according to the scale published by Jovanovic 
 
et al
 
.
[14]. Insulin administration was initiated at the time GDM was
diagnosed and continued through the end of pregnancy. The
initial total insulin dose was 0.8 U/kg per day if gestation < 26
weeks or 0.9 U/kg per day if gestation 
 
≥
 
 26 weeks [17]. In addition
to insulin therapy, subjects were instructed to follow a recom-
mended dietary regimen of 30 kcal/kg if their current body weight
was within 80–120% of ideal body weight, 24 kcal/kg if their
weight was within 121–150% of their ideal weight, or 12 kcal/kg
if their weight was > 150% of their ideal body weight.
Before the initiation of insulin therapy, subjects had stand-
ardized meal tests performed on three consecutive days (without
insulin on day 1 and with IAsp and HI in random sequence on
days 2 and 3) at the start of the trial. A second set of meal tests
was performed on two consecutive days (with IAsp and HI in
random sequence) after 6 weeks of basal-bolus treatment. All
meal tests were conducted in the morning after an overnight
fast. The mealtime tests were conducted in a crossover manner
and were not limited to the specific mealtime insulin that
subjects had been receiving during the study. A mixed meal test
was chosen because it is more physiological than a glucose load,
but is still standardized and reproducible. Determining the
effect of prandial insulins on postprandial glucose required a
standardized meal. Women were tested during different stages
of gestation and the crossover design allowed each woman to
serve as her own control. During the paired meal tests, both at
baseline and at 6 weeks, the same dose of either HI or IAsp was
given on both days and was two-ninths of the total daily insulin
requirement [17]. The mixed meal test consisted of 40%
carbohydrate, 20% protein and 40% fat and was calculated to
provide 20% of the woman’s daily caloric requirement [17].
Blood samples were drawn for plasma glucose, serum insulin
and C-peptide determinations at the following time points: –30,
0, 15, 30, 60, 90, 120, 180 and 240 min after the meal, and for
proinsulin at 0 min only. No other food was consumed during
this time, but symptomatic hypoglycaemia was treated with oral
glucose tablets. Since each woman had meal tests using IAsp
and regular HI, the values from the two tests were compared
using paired 
 
t
 
-tests. Overall glycaemic control was assessed by
HbA
 
1c
 
 after 6 weeks of treatment, during the 36–38th weeks of
pregnancy and at 6 weeks postpartum. HbA
 
1c
 
 at screening was
assessed at the local trial site and all the subsequent HbA
 
1c 
 
values
were assessed at the central laboratory (MRL International,
Highland Heights, KY, USA).
Safety assessments were based on adverse events (AEs),
hypoglycaemic episodes, insulin-specific antibodies and
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cross-reactive insulin antibodies. Subjects recorded meter-
measured BG values and symptoms of hypoglycaemia associated
with BG meter readings. A minor hypoglycaemic episode was
defined as an episode with symptoms consistent with hypo-
glycaemia (i.e. palpitations, tiredness, sweating, strong hunger,
dizziness, tremour, etc.) with a confirmed BG meter reading
< 2.8 mmol/l (50 mg/dl) and which was managed by the subjects
themselves. Serum samples for determination of IAsp and HI
concentrations, as well as insulin antibody binding, were
collected prior to initiation of insulin, after 6 weeks of insulin
therapy, during the 36–38th weeks of pregnancy and at 6 weeks
postpartum. Samples were obtained from fasting individuals
to minimize interference from administered HI and IAsp.
Antibody binding specific to IAsp or HI was determined by
radioimmunoassay and was expressed as the percent bound
radioactivity used to assay the sample in a subtraction assay
[18–20]. The value of cross-reacting antibody binding was
calculated as the total HI binding that was inhibited by IAsp.
At birth, cord blood samples were collected for analysis of insulin
concentration (IAsp and HI) and insulin antibody binding.
 
Statistical methods
 
Statistical analyses were based on the intent-to-treat population.
Missing values of HbA
 
1c
 
 were imputed using the last observa-
tion carried forward. The parameters in the meal test (which
followed a cross-over design) were analysed using paired 
 
t
 
-
tests. A 5% level of significance was used throughout the study.
All analyses were carried out using the two-sided tests. Results
are presented as mean 
 
±
 
 
 
SD
 
. The glucose area under the curve
(AUC), measuring the total glycaemic exposure, was calculated
using the trapezoidal rule [21].
 
Results
 
Demographic characteristics and subject disposition
 
Subject demographics and baseline characteristics are shown
in Table 1. Most subjects were Latino and the distributions of
ethnicity were similar in the two treatment groups. The group
randomized to regular insulin had a slightly higher body mass
index but the difference was not statistically significant.
Twenty-seven subjects were randomly assigned to receive
either IAsp (
 
N
 
 = 14) or HI (
 
N
 
 = 13). Thirteen (93%) subjects
in the IAsp group and nine (69%) in the HI group completed
the study. Four subjects discontinued the study since they
delivered early and one subject discontinued due to the inability
during the meal test to provide adequate blood samples
because of excessive clotting.
 
HbA
 
1c
 
Both treatment groups maintained good overall glycaemic
control during the study (beginning and end of the study
HbA
 
1c 
 
values 
 
≤
 
 6%). Mean HbA
 
1c 
 
values for the IAsp and HI
groups were 5.2% during the 36–38th week of pregnancy and
5.4% at 6 weeks postpartum.
 
Glucose, C-peptide, insulin and proinsulin values during 
the meal test
 
The glucose profiles during the meal tests at week 6 are shown
in Fig. 1. Thirty minutes after the meal, the women had a lower
mean glucose concentration with IAsp than with HI (4.7
 
±
 
 0.19 mmol/l vs. 5.1 
 
±
 
 0.23 mmol/l, respectively; 
 
P
 
 = 0.0278).
The mean peak glucose concentration occurred at the 60-min
time point for both treatment groups, but was significantly
lower with IAsp than with HI (5.4 
 
±
 
  0.21  mmol/l vs. 6.2
 
±
 
 0.33 mmol/l, respectively; 
 
P
 
 < 0.0097). The average glucose
AUC and 
 
C
 
max
 
 values were significantly lower for IAsp than
for HI (Fig. 1).
The average values for glucose, C-peptide, insulin and
fasting proinsulin during the meal tests at baseline, week 0,
and week 6 are summarized in Table 2. IAsp was effective in
Table 1 Demographics and baseline characteristics
Insulin aspart 
N = 14
Regular insulin 
N = 13
Age (years)* 31.6 ± 5.9 29.7 ± 6.9
Race, n (%):
Black 0 1 (8)
White 4 (29) 1 (8)
Hispanic 9 (64) 11 (85)
Native American 1 (7) 0
Parity 2.2 2.7
Height (cm)* 157.6 ± 6.9 155.6 ± 5.5
Weight (kg)* 72.9 ± 13.1 80.8 ± 16.1
Body mass index (kg/m2)* 29.3 ± 4.7 33.2 ± 5.7
HbA1c (%) 5.1 ± 0.4 5.3 ± 0.3
*Values are mean ± SD.
Differences between treatment groups were not statistically 
significant for all parameters.
FIGURE 1 Average glucose profile during the meal tests. Average glucose 
(mmol/l) concentrations during the 4-h meal test with insulin aspart 
(IAsp) or regular insulin (HI).  , HI;  , IAsp.
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reducing the postprandial glucose concentration from baseline.
The average glucose values during the meal test at week 6 were
slightly lower than at week 0 for both treatment groups.
However, treatment with IAsp during the meal test at week 6
led to lower glycaemic exposure than treatment with HI, as
demonstrated by the significantly lower change from baseline
glucose values (Table 2). The response to the follow-up meal
tests was similar in the two groups, but both had lower peak
glucose and lower AUC with IAsp. Both treatment groups had
a slight increase in the average insulin at week 6 (reflecting
the sum of endogenous insulin response plus exogenously
administered mealtime insulin). However, the mean change
from baseline insulin values at week 6 were similar for both
treatment groups (Table 2). The contribution of endogenous
insulin to the overall insulin profile was ascertained by measure-
ment of C-peptide values, which were slightly lower for both
IAsp and HI treatments at week 6 than at week 0. However,
IAsp treatment resulted in a significantly lower C-peptide
value at week 6 than did HI treatment (Table 2). The proinsulin
concentrations for both treatments (reflecting overall endo-
genous insulin production) were lower at week 6 than at week
0 because of the lower demand for endogenous insulin after
6 weeks of treatment. However, the change from baseline
values were not significantly different between treatments.
 
Safety profile
 
Fourteen subjects reported a total of 27 AEs: eight (57%)
subjects with 16 AEs in the IAsp group and six (46%) subjects
with 11 AEs in the HI group. All reported AEs were not
uncommon for the study population. In both treatment groups,
the most frequently reported AE was upper respiratory tract
infection [IAsp two (14%) subjects with two (12%) episodes;
HI three (23%) subjects with three (27%) episodes]. The
investigators considered fatigue (one subject) and somnolence
(one subject) in the IAsp treatment group, and injection site
reaction (IAsp, one subject; HI, two subjects) to be the only
AEs possibly/probably related to the study drug.
Table 2 Time-adjusted* average glucose, C-peptide, insulin and proinsulin values during the meal tests
Week Treatment‡ 
Observed data* Change from baseline
N Mean ± SD Mean ± SD P-value§
Glucose (mmol/l)
Baseline No exogenous insulin 20 5.3 ± 0.43
Week 0 Insulin aspart 19 4.9 ± 0.59 –0.41 ± 0.47 0.319
Regular insulin 19 5.1 ± 0.36 –0.28 ± 0.34
Week 6 Insulin aspart 15 4.2 ± 0.57 –1.09 ± 0.55 0.003
Regular insulin 15 4.8 ± 0.86 –0.54 ± 0.74
Insulin (pmol/l)
Baseline No exogenous insulin 20 210 ± 102
Week 0 Insulin aspart 19 288 ± 120 78 ± 54 0.393
Regular insulin 19 276 ± 138 60 ± 66
Week 6 Insulin aspart 15 318 ± 96 114 ± 84 0.611
Regular insulin 15 306 ± 120 108 ± 96
C-peptide (nmol/l)
Baseline No exogenous insulin 20 1.50 ± 0.60
Week 0 Insulin aspart 20 1.26 ± 0.46 –0.23 ± 0.23 0.076
Regular insulin 19 1.36 ± 0.46 –0.17 ± 0.27
Week 6 Insulin aspart 15 0.93 ± 0.46 –0.50 ± 0.67 0.027
Regular insulin 15 1.13 ± 0.50 –0.30 ± 0.70
Fasting proinsulin (pmol/l)†
Baseline No exogenous insulin 20 10.7 ± 20.6
Week 0 Insulin aspart 20 9.7 ± 17.6 –1.1 ± 3.4 0.154
Regular insulin 17 11.1 ± 21.8 –0.1 ± 1.6
Week 6 Insulin aspart 14 3.8 ± 3.6 –3.0 ± 5.9 0.156
Regular insulin 15 5.3 ± 5.2 –1.1 ± 5.9
*The average values (determined at the time points: 30 and 0 min before the meal and at times 15, 30, 60, 90, 120, 180 and 240 min after the 
meal) were adjusted for possible differences in the duration of measurements and therefore represent the average concentration of the parameter 
over the time course of measurements.
†Proinsulin was measured only at time = 0 min before each meal test.
‡Treatment received for meal test.
§P-value for comparison between treatments was obtained from ANOVA, with treatment included as fixed effect and baseline average values as 
covariate.
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Hypoglycaemic episodes
Symptomatic hypoglycaemic episodes were reported by 19
subjects: 10 (71%) in the IAsp group (53 events) and nine
(69%) in the HI group (23 events). Minor hypoglycaemic
episodes (BG < 50 mg/dl) were reported by 16 subjects: 11
(79%) in the IAsp group (52 episodes) and five (39%) in the HI
group (nine episodes). Half of the total minor hypoglycaemic
episodes reported in the IAsp group were reported by two
subjects prone to hypoglycaemia (subjects with 15 and 11
episodes). Most of the hypoglycaemic episodes occurred
during the daytime hours (06.00–22.00 h) by 11 subjects (46
episodes) in the IAsp group and by five subjects (seven episodes)
in the HI group. Four IAsp-treated subjects had six episodes of
nocturnal hypoglycaemia (22.00–06.00 h) and one HI-treated
subject had two episodes. No hypoglycaemic episodes required
the assistance of another person.
Insulin-specific antibodies and cross-reacting insulin 
antibodies
Cross-reacting antibody binding, human insulin-specific
antibody binding and IAsp-specific antibody binding were
determined before initiation of insulin therapy (visit 2), at 6 weeks
of insulin therapy (visit 5), at 36–38th weeks of gestation
(visit 7) and at 6 weeks postpartum (visit 9). Antibody binding
specific to IAsp and HI remained relatively low for most of
the subjects in both treatment groups throughout the study. At
baseline, the mean (± SD) cross-reacting antibody binding was
0.2 ± 0.3% for both IAsp and HI groups. Mean cross-reacting
antibody binding increased slightly to 1.4  ±  3.0% and 2.3
± 5.4% for the IAsp group and 1.5 ± 2.3% and 6.5 ± 13.7%
for the HI group, at visits 7 and 9, respectively. The increase in
the mean value of the cross-reacting antibody binding for
the IAsp group was largely attributable to one subject who
had a binding value of 10.1% at visit 7 and a value of 19.2%
at visit 9. One subject in the HI group had a similar increase in
cross-reacting antibody binding of 47.0% at visit 9. However,
these subjects did not require additional insulin to maintain
normal overall glycaemic control (HbA1c at the end of the
study < 5.3%).
Examination of cord blood serum for the presence of insulin
Cord blood serum samples, collected immediately after
delivery, were analysed for the presence of IAsp and HI. The
lower limit of detection for HI was 11.0 pmol/l and for IAsp
5.3 pmol/l. During delivery, the IAsp concentration in the cord
blood samples for three subjects in the IAsp treatment group
(but not receiving intravenous IAsp during labour) were below
the lower limit of detection. However, the IAsp concentration
in the cord blood for one subject (randomized to the IAsp
treatment group and receiving intravenous IAsp during
labour) was 33 pmol/l. Four subjects in the HI treatment group
showed an elevated level of HI in the cord blood serum sample
that was particularly high in one subject (211 pmol/l) receiving
intravenous HI treatment during labour.
In the cord blood serum samples, antibody binding specific
to IAsp and to HI was similarly low for both treatment groups
(< 0.5% binding of the specific antibodies). Although the IAsp
concentration in the cord blood serum for one subject was
33 pmol/l, the antibody binding for the cord blood sample of
this subject was low. Similarly, antibody binding in the cord
blood serum sample that had a measurable HI concentration
(211 pmol/l) also had low insulin-specific and cross-reacting
antibody binding.
Pregnancy outcome—neonatal assessment
The pregnancy outcomes (determined by the neonatal assess-
ment: weight, length and physical examination findings) were
similar in both treatment groups. The mean weights (IAsp
3.1 ± 0.5 kg; HI 3.0 ± 0.5 kg) and lengths (IAsp 49 ± 2.3 cm;
HI 48 ± 2.4 cm) of the infants were similar between treatment
groups. In this study, the maximum birth weight of an infant
was 3.8 kg in the HI group and 4.1 kg in the IAsp group. No
case of macrosomia was reported. Two infants in the HI group
had abnormal physical examination findings (one infant diag-
nosed with Down’s syndrome and one infant with petechiae
on neck and upper chest from a tight umbilical nuchal cord).
Another subject in the IAsp group had a fetus that died in utero
during week 40 (fetal death due to umbilical cord strangula-
tion). These events were deemed by the investigators as having
an unlikely relationship to the study drug.
Discussion
In this study, the greater reduction in the change from baseline
average glucose values has demonstrated that subjects had
better postprandial glycaemic control when they were treated
with IAsp than with regular insulin. This finding is similar to
a previous study using insulin lispro [16]. Studies in healthy
volunteers have demonstrated that subcutaneously injected
IAsp reaches peak plasma concentrations that are higher and
occur earlier than those of regular HI, leading to a faster onset
of blood glucose-lowering action [22–24]. Lindholm et al. [22]
have shown that in healthy volunteers, the time to maximum
serum glucose concentration after subcutaneous injection
occurs > 1 h earlier for IAsp than for an equal dose of regular
HI. Maternal postprandial glucose (1 h after beginning the
meal) correlates positively with neonatal birth weight in
pregnancies complicated by diabetes [25–27]. Adjustment of
insulin therapy in gestational diabetes to normalize post-
prandial glucose levels leads to a decreased rate of macrosomia
and lower rates of caesarean sections [27]. The neonatal birth
weights were similar in the two groups and no case of macro-
somia was reported.
Although more hypoglycaemic episodes were reported in the
IAsp than in the HI treatment group, no major hypoglycaemic
events (requiring the assistance of another individual) were
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reported in the study. Most of the hypoglycaemic episodes
occurred during daytime hours, which allowed subjects to
treat these episodes easily.
The mean change from baseline average plasma insulin
values at week 6 was similar for the two treatment groups. The
insulin assay used in this study measured total insulin (i.e. both
exogenous and endogenous insulin). Both treatment groups
had a slight increase in the insulin concentration between week
0 and week 6. This increase was not due to the endogenous
insulin, as C-peptide levels were lower at week 6. The increase
in insulin may be due to the increase in the total daily insulin
dose resulting from the insulin dose titration.
The contribution of the endogenous insulin, measured by the
C-peptide response, showed that the demand for endogenous
insulin was lower after IAsp injection than after HI injection,
despite the fact that the same dose of insulin was used. Such
findings indicate that following sustained basal-bolus insulin
therapy, less demand was placed upon the β-cells after IAsp
injection than after HI injection. This observation probably
reflects the fact that the pharmacokinetics of IAsp provides
mealtime coverage of glycaemic needs by achieving higher
peak insulin concentrations in less time and with a shorter
duration of action than HI, thereby reducing the demand for
endogenous insulin secretion during the meal test [28]. In this
study, all subjects remained in good overall glycaemic control
(HbA1c at end of study was ≤ 6.0%).
Specific antibody binding to IAsp and regular HI remained
relatively low (< 1.5% binding of specific antibody) for both
treatment groups throughout the study. Increases in cross-
reacting antibody binding have previously been observed in
patients treated with IAsp and HI in a 12-month controlled
trial in subjects with Type 1 diabetes [18]. However, the
increase in the cross-reacting antibody binding at 3 months was
transient and returned to near normal by 12 months. Although
the reason for the rise in specific antibodies is unknown, the
increase in antibodies was not accompanied by a deterioration
of glycaemic control and did not require an increase in insulin
dose for these subjects to maintain glycaemic control.
Earlier studies have shown that insulin–antibody complexes
may cross the placenta and be associated with the development
of macrosomia in the infant [15]. No data were previously
available to show whether IAsp crossed the placenta during
fetal development. In this study, a cord blood sample taken
after delivery from one subject was found to contain IAsp
(33 pmol/l). This was the only subject to receive IAsp during
delivery. The presence of IAsp in the cord blood sample of this
subject may have occurred as a result of the disruption in the
uterine–placental barrier during delivery. Since the sample was
collected during delivery, it is not possible to determine
whether IAsp crosses the placenta during development of the
fetus. Another insulin analogue, insulin lispro, did not cross
the human placenta in an in vitro perfusion study [29]. Infusion
of insulin during labour may be associated with increased
insulin concentrations in the cord blood. Since there were only
two subjects in this study who had insulin infusion during
delivery, further study is necessary to determine the safety of
such insulin infusion during labour. Overall, IAsp appeared to
be of low immunogenicity in women with GDM.
In conclusion, this study has demonstrated that the overall
safety and effectiveness of IAsp was comparable to regular HI
in pregnant women with GDM. IAsp was more effective than
regular HI in providing postprandial glycaemic control in
women with GDM.
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